MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Yan, S. Betty, Um, Suzane L., Peek, Victoria L., Stephens, Jennifer R., Zeng, Wei, Konicek, Bruce W., Liu, Ling, Manro, Jason R., Wacheck, Volker, Walgren, Richard A.Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-017-0545-x
Date:
November, 2017
File:
PDF, 1.58 MB
english, 2017